To further examine the potential of 4-sulfonic calix[6]arene as a pharmacological tool to inhibit AIM2-dependent responses in vivo, we assessed T cell loss after stroke in vehicle or 4-sulfonic calix[6]arene-treated mice (Figure 5E). This evidence concerns the gene AIM2 and stroke disorder.